PhD, Economics
MHA, Health Administration
MA, Physiology and Pharmacology
Duke University, Durham, NC
Josephine Mauskopf, PhD, MHA, is Distinguished Fellow of Health Economics at RTI-HS. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, multiple sclerosis, bipolar disease, breast cancer, and HIV infection as well as for new vaccination programs. She has estimated the cost effectiveness of antiretroviral drugs, as well as drugs for treating Alzheimer’s disease, fungal infections, herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, influenza vaccination, and primary pulmonary hypertension. Dr. Mauskopf also has estimated the impact of an antidepressant on work and social disability. Dr. Mauskopf has performed many strategic literature reviews that have been published in peer-reviewed journals, including reviews of cost of care and clinical practice guidelines for Alzheimer’s disease, impact of social determinants of health on meningococcal vaccination, impact of COVID-19 on routine immunization programs, alternative modeling methods for vaccination programs cost of care for treatment-resistant depression, a review of the methods used to estimate the cost-effectiveness of vaccine programs using dynamic programming models, cost-effectiveness of tiotropium for chronic obstructive pulmonary disease, and treatments for uterine fibroids. Dr. Mauskopf has developed Markov models of disease progression for lung cancer and HIV infection and has developed simulation models of time spent in the operating and recovery rooms and of disease progression for HIV infection. Dr. Mauskopf has used multi-criteria decision analysis (MCDA) to estimate the likelihood of reimbursement for products with different attributes and to estimate the impact of benefits and risks on drug prescribing decisions.
Dr. Mauskopf has worked at RTI since 1983 but with periods spent at other organizations including as Vice President at MEDTAP International, Department Head of Economics Research at Burroughs Wellcome Co., and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc. Dr. Mauskopf has completed an 8-year term as Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She received the ISPOR award for Excellence in Application of Pharmacoeconomics and Outcomes Research in 2006, a ISPOR Avedis Donabedian Lifetime Achievement Award in 2013, and in 2019 she received the ISPOR Marilyn Dix Smith Leadership Award. She has cochaired two ISPOR Task Forces one for Guidelines for Budget Impact Analysis and one for Economic Evaluation Methods for Vaccination Programs. She was also a ISPOR Task Force member of the CHEERS Task Force Guidelines for Reporting Health Economic Analyses. She has presented her research at numerous national and international symposia. She has also published extensively in journals, including Journal of the American Medical Association, Journal of Pediatrics, Pediatric Infectious Disease, PharmacoEconomics, Value in Health, Medical Care, American Journal of Public Health, Health Services Research, American Journal of Alzheimer’s Disease and Other Dementias, and Journal of Nutrition, Health, and Aging.